Izotropic’s IzoView Breast CT to Offer Patent-Pending Personalised Radiation Dose

The optical pre-scan system captures a radiation-free image of the breast and uses it to calculate a personalised radiation dose, customised to each patient’s breast size

Izotropic Corporation, a medical device company commercialising innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the integration of a new patent-pending radiation dose personalisation feature into its flagship device, the IzoView Breast CT Imaging System. This proprietary capability positions IzoView as the first breast CT system to offer real-time customised radiation dosing, using an integrated radiation-free optical pre-scan feature and proprietary software.

The optical pre-scan system captures a radiation-free image of the breast and uses it to calculate a personalised radiation dose, customised to each patient’s breast size. The system uses this pre-scan data and dose reference models developed at UC Davis Medical Centre (UC Davis), where breast CT technology was founded and advanced through over two decades of academic research and clinical trials involving hundreds of patients. Izotropic holds the exclusive global rights to breast CT technology, and IzoView has been engineered as the commercial device model.

By eliminating the need for manual dose selection by a technician, the optical pre-scan system streamlines exam setup and contributes to operational efficiency. Combined with IzoView’s compression-free, contact-free design, the system is intended to enhance patient comfort and support compliance in both screening and diagnostic environments.